Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2007

01-10-2007 | Original Article

Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours

Authors: S. A. Veltkamp, H. Rosing, A. D. R. Huitema, M. R. Fetell, A. Nol, J. H. Beijnen, J. H. M. Schellens

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2007

Login to get access

Abstract

Purpose

To explore the pharmacokinetics (PKs) of paclitaxel and two major metabolites after three single oral administrations of a novel drinking solution and two capsule formulations in combination with cyclosporin A (CsA) in patients with advanced cancer. Moreover, the tolerability and safety of the formulations was studied. In addition, single nucleotide polymorphisms in the multidrug resistance (MDR1) gene were determined.

Patients and methods

Ten patients were enrolled and randomized to receive CsA 10 mg/kg followed by oral paclitaxel 180 mg given as (1) drinking solution (formulation 1), (2) capsule formulation 2B, and (3) capsule formulation 2C on day 1, 8, or 15.

Results

The median C max of paclitaxel was 0.42 (0.23–0.96), 0.48 (0.08–0.59), and 0.39 (0.11–1.03) μg/ml and the area under the plasma concentration–time curve was 2.83 (1.69–5.12), 2.01 (1.57–3.04), and 2.67 (1.05–3.61) μg h/ml following administration of formulations 1, 2B, and 2C, respectively. The novel formulations were tolerated after single oral dose without causing relevant gastrointestinal or haematological toxicity.

Conclusions

The PK and metabolism of paclitaxel were comparable between the oral formulations co-administered with CsA.
Literature
1.
Bardelmeijer HA, Ouwehand M, Malingré MM, Schellens JHM, Beijnen JH, van Tellingen O (2002) Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother Pharmacol 49:119–125PubMedCrossRef
2.
Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J (1990) Rapid and simple method for purification of nucleic acids. J Clin Microbiol 28:495–503PubMed
3.
Bosch TM, Meijerman I, Beijnen JH, Schellens JHM (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253–285PubMedCrossRef
4.
Boudreaux JP, Hayes DH, Mizrahi S, Maggiore P, Blazek J, Dick D (1993) Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant. Transplant Proc 25:1875PubMed
5.
Britten CD, Baker SD, Denis LJ, Denis LJ, Johnson T, Drengler R, Siu LL, Duchin K, Kuhn J, Rowinsky EK (2000) Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. Clin Cancer Res 6:3459–3468PubMed
6.
Chang RK, Shojaei AH (2004) Effect of a lipoidic excipient on the absorption profile of compound UK 81252 in dogs after oral administration. J Pharm Pharm Sci 7:8–12PubMed
7.
Chang T, Benet LZ, Hebert MF (1996) The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 59:297–303PubMedCrossRef
8.
de Jonge ME, Huitema ADR, Schellens JHM, Rodenhuis S, Beijnen JH (2005) Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. Br J Clin Pharmacol 59:325–334PubMedCrossRef
9.
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478PubMedCrossRef
10.
Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199PubMedCrossRef
11.
Kivisto KT, Kroemer HK, Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523–530PubMed
12.
Kruijtzer CM, Beijnen JH, Schellens JHM (2002) Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7:516–530PubMedCrossRef
13.
Malingré MM, Schellens JHM, van Tellingen O, Rosing H, Koopman FJ, Duchin K, ten Bokkel Huinink WW, Swart M, Beijnen JH (2000) Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. Anticancer Drugs 11:813–820PubMedCrossRef
14.
Malingré MM, Meerum Terwogt JM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JHM (2000) Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 18:2468–2475PubMed
15.
Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JHM (2001) A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol 47:347–354PubMedCrossRef
16.
Malingré MM, Beijnen JH, Rosing H, Koopman FJ, van Tellingen O, Duchin K, ten Bokkel Huinink WW, Swart M, Lieverst J, Schellens JHM (2001) The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anticancer Drugs 12:351–358PubMedCrossRef
17.
Malingré MM, Beijnen JH, Schellens JHM (2001) Oral delivery of taxanes. Invest New Drugs 19:155–162PubMedCrossRef
18.
Malingré MM, Rosing H, Koopman FJ, Schellens JHM, Beijnen JH (2001) Performance of the analytical assays of paclitaxel, docetaxel, and cyclosporin in a routine hospital laboratory setting. J Liq Chromatogr Relat Technol 24:2697–2717CrossRef
19.
Malingré MM, Schellens JHM, van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, ten Bokkel Huinink WW, Beijnen JH (2001) The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer 85:1472–1477PubMedCrossRef
20.
Malingré MM, ten Bokkel Huinink WW, Duchin K, Schellens JHM, Beijnen JH (2001) Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. Anticancer Drugs 12:591–593PubMedCrossRef
21.
Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JHM (1999) Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5:3379–3384PubMed
22.
Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112–2115PubMed
23.
Sparreboom A, van Asperen J, Mayer U, et al (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031–2035PubMedCrossRef
24.
Sparreboom A, van Zuylen L, Brouwer E, et al (1999) Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59:1454–1457PubMed
25.
Vainchtein LD, Thijssen B, Stokvis E, Rosing H, Schellens JHM, Beijnen JH (2006) A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry. Biomed Chromatogr 20:139–148PubMedCrossRef
26.
van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH (1998) Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4:2293–2297PubMed
27.
van Tellingen O, Huizing MT, Panday VR, Schellens JHM, Nooijen WJ, Beijnen JH (1998) Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81:330–335CrossRef
28.
van Zuylen L, Karlsson MO, Verweij J, et al (2001) Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 47:309–318PubMedCrossRef
29.
van Zuylen L, Verweij J, Sparreboom A (2001) Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19:125–141PubMedCrossRef
30.
Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, Huitema ADR, Nuijen B, Nol A, Neijnen JH, Schellens JHM (2006) A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 95:729–734PubMedCrossRef
31.
Veltkamp SA, Alderden-Los C, Sharma A, Rosing H, Beijnen JH, Schellens JHM (2007) A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. Cancer Chemother Pharmacol 59:43–50PubMedCrossRef
32.
Webster LK, Linsenmeyer ME, Rischin D, Urch ME, Woodcock DM, Millward MJ (1997) Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemother Pharmacol 39:557–560PubMedCrossRef
33.
Wolff AC, Donehower RC, Carducci MK Cardussi MA, Brahmer JR, Zabelina Y, Bradley MO, Anthony FH, Swindell CS, Witman PA, Webb NL, Baker SD (2003) Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 9:3589–3597PubMed
Metadata
Title
Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours
Authors
S. A. Veltkamp
H. Rosing
A. D. R. Huitema
M. R. Fetell
A. Nol
J. H. Beijnen
J. H. M. Schellens
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-006-0405-4

Other articles of this Issue 5/2007

Cancer Chemotherapy and Pharmacology 5/2007 Go to the issue

Original Article

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

Original Article

Short hairpin RNAs targeting Bcl-xL modulate senescence and apoptosis following SN-38 and irinotecan exposure in a colon cancer model

Original Article

Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice

Original Article

WP760, a melanoma selective drug

Original Article

Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines

Original Article

Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits